Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 10/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7145620 | 0.99 | SCN2A (0.41) | SCN2ACNR2CNR1SPHK1NPY5R | |
| SCHEMBL7143632 | 0.91 | SPHK1 (0.43) | SCN2ACNR2CNR1SPHK1NPY5R | |
| SCHEMBL8108537 | 0.86 | SPHK1 (0.42) | SCN2ACNR2CNR1SPHK1HPGDS | |
| SCHEMBL7140243 | 0.85 | SCN2A (0.42) | SCN2ACNR2CNR1SPHK1NPY5R | |
| SCHEMBL8124149 | 0.80 | HPGDS (0.40) | SCN2ACNR2CNR1SPHK1NPY5R | |
| SCHEMBL7135177 | 0.77 | SCN2A (0.41) | SCN2ACNR2CNR1SPHK1NPY5R | |
| SCHEMBL7145617 | 0.76 | SCN2A (0.41) | SCN2ACNR2CNR1SPHK1NPY5R | |
| SCHEMBL7143629 | 0.72 | SPHK1 (0.43) | SCN2ACNR2CNR1SPHK1NPY5R | |
| SCHEMBL7140240 | 0.71 | SCN2A (0.42) | SCN2ACNR2CNR1SPHK1NPY5R | |
| SCHEMBL7139526 | 0.70 | SCN2A (0.50) | SCN2ACNR2CNR1NPY5RHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515133-B1 | Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-6121260-A | Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives | NEUROGEN CORPORATION (US) | 2000-09-19 | — | — | US | disclosed |